INBS

Intelligent Bio Solutions Inc. (INBS) - 10-K Summary

Business Context and Reporting Period

Company: Intelligent Bio Solutions Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: INBS is a medical technology company focused on non-invasive testing solutions. Its primary commercial product is the Intelligent Fingerprinting (IFP) System, which uses fingerprint sweat to detect drugs of abuse. The company operates globally with a manufacturing facility in Cambridge, UK, and offices in Australia and the US. In fiscal 2025, the company revised its reportable segments from product-based to a region-focused structure (UK, APAC, Americas, Rest of World).

Key Financial Metrics

Note: The filing text does not provide a specific total debt figure, but notes a current portion of notes payable of $197,146 and a significant liability of $2,172,108 payable to the Australian Government regarding a grant acquittal.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 1.9% ($59,249) primarily due to instability in the UK construction sector, reducing sales of IFP readers. However, cartridge sales increased by 13.7%.
• Margin Compression: Gross profit margin decreased by 4.96 percentage points to 40.85%, driven by an 8.90% year-over-year increase in minimum wages for factory staff and increased direct labor costs.
• Increased Operating Expenses: Development and regulatory approval expenses rose by 43.2% ($722,707) to $2.4 million, driven by clinical trials and FDA 510(k) submission costs. Selling, general, and administrative (SG&A) expenses decreased by 4.0%.
• Impairment Loss: The company recognized a $220,062 impairment loss on long-lived assets (construction in progress) related to the Australian manufacturing facility project, which was terminated.
• Grant Liability: A grant acquittal audit resulted in a $2.17 million liability payable to the Australian Government, recorded in accounts payable and accrued expenses.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management believes cash on hand ($1.02 million) is insufficient to fund operations for the next 12 months without additional financing.
• Capital Raising: The company raised approximately $4.6 million during the fiscal year through an underwritten public offering and an At-The-Market (ATM) offering. Further capital raises are required to continue operations.
• Regulatory Progress: The company submitted a 510(k) pre-market notification to the FDA in December 2024 for its opiate test system. Successful clearance is critical for US market expansion.
• Intellectual Property Uncertainty: Development of the Biosensor Platform Technology (BPT) is postponed indefinitely. The IP reverted to the University of Newcastle following the liquidation of the licensor (LSBD), and licensing terms cannot be finalized until the liquidation is complete.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting, citing a lack of documented policies, insufficient review procedures, and limited accounting personnel.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline and terms of any new financing arrangements to address the "substantial doubt" regarding going concern status.
• Grant Repayment: Confirm the repayment schedule and terms for the $2.17 million liability owed to the Australian Government.
• FDA Clearance Status: Monitor the status of the 510(k) submission for the opiate test system, as US market entry is a primary growth driver.
• BPT Licensing: Track the liquidation status of LSBD and any updates on the re-licensing of Biosensor IP from the University of Newcastle.
• Internal Control Remediation: Review progress on remediation plans for material weaknesses in financial reporting controls.